ABEO Stock Price, Abeona Therapeutics Inc Quote, Chart

Market Summary

USD3.28+0.09

Market Closed

2.82%

ABEO Stock Price

View Fullscreen

ABEO RSI Chart

ABEO Valuation

Market Cap

89.7M

Price/Earnings (Trailing)

-1.66

Price/Sales (Trailing)

25.15

Price/Free Cashflow

-2.4

ABEO Price/Sales (Trailing)

ABEO Profitability

Return on Equity

-365.49%

Return on Assets

-84.67%

Free Cashflow Yield

-41.62%

ABEO Fundamentals

ABEO Revenue

Revenue (TTM)

3.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ABEO Earnings

Earnings (TTM)

-54.2M

Earnings Growth (Yr)

-132.99%

Earnings Growth (Qtr)

-40.17%

Breaking Down ABEO Revenue

Last 7 days

-56.7%

Last 30 days

-55.3%

Last 90 days

-30.1%

Trailing 12 Months

4.8%

How does ABEO drawdown profile look like?

ABEO Financial Health

Current Ratio

4.15

ABEO Investor Care

Shares Dilution (1Y)

44.23%

Diluted EPS (TTM)

0.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	4.6M	3.6M	3.6M
2022	1.7M	1.6M	1.5M	1.4M
2021	0	0	0	1.8M
2020	0	0	10.0M	12.2M
2018	6.9M	7.5M	9.0M	9.3M
2017	1.0M	843.0K	878.0K	837.0K
2016	1.3M	1.4M	1.5M	1.1M
2015	358.9K	672.8K	986.6K	1.3M
2014	1.0M	806.0K	853.0K	45.0K
2013	3.8M	3.6M	2.9M	2.0M
2012	3.5M	4.1M	3.9M	4.4M
2011	2.0M	1.9M	1.9M	1.8M
2010	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Abeona Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 25, 2024	o'malley brendan m.	bought	27,864	3.24	8,600	svp, general counsel
Apr 25, 2024	vazzano joseph walter	bought	17,609	3.14	5,608	chief financial officer
Mar 15, 2024	vazzano joseph walter	sold (taxes)	-5,722	8.14	-703	chief financial officer
Mar 04, 2024	o'malley brendan m.	sold (taxes)	-1,429	7.81	-183	svp, general counsel
Feb 06, 2024	seshadri vishwas	bought	87,800	4.39	20,000	chief executive officer
Jan 17, 2024	alvino mark	sold	-36,199	5.11	-7,084	-
Oct 16, 2023	seshadri vishwas	sold (taxes)	-749	4.14	-181	chief executive officer
Sep 29, 2023	o'malley brendan m.	sold (taxes)	-25,769	3.93	-6,557	svp, general counsel
Sep 29, 2023	seshadri vishwas	sold (taxes)	-52,229	3.93	-13,290	chief executive officer
Sep 29, 2023	vazzano joseph walter	sold (taxes)	-24,483	3.93	-6,230	chief financial officer

Which funds bought or sold ABEO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-54.82	-8,000	15,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	793	796,152	862,885	-%
Apr 24, 2024	Hartford Financial Management Inc.	unchanged	-	1,612	5,220	-%
Apr 15, 2024	Palumbo Wealth Management LLC	new	-	104,168	104,168	0.05%
Mar 11, 2024	VANGUARD GROUP INC	added	46.25	2,346,810	5,516,670	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-49,000	-	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	95.86	12,873,800	22,547,500	0.67%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	204,844	204,844	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-54.28	-714,000	850,000	-%
Feb 14, 2024	LPL Financial LLC	added	20.00	44,058	146,993	-%

Are Funds Buying or Selling ABEO?

Are funds buying ABEO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ABEO

No. of Funds

Unveiling Abeona Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	point72 asset management, l.p.	6.4%	1,649,740	SC 13G/A
Feb 14, 2024	armistice capital, llc	4.99%	1,301,114	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	4.2%	1,086,956	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	2,499,781	SC 13G/A
Feb 12, 2024	flynn james e	3.39%	869,565	SC 13G/A
Jan 10, 2024	integrated core strategies (us) llc	5.5%	1,363,572	SC 13G/A
Dec 04, 2023	integrated core strategies (us) llc	5.4%	1,334,725	SC 13G
Jul 06, 2023	adage capital partners gp, l.l.c.	15.32%	3,249,994	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	7.4%	1,150,648	SC 13G/A
Feb 14, 2023	armistice capital, llc	6.44%	1,106,000	SC 13G

Recent SEC filings of Abeona Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 24, 2024	8-K	Current Report
Apr 22, 2024	8-K	Current Report
Mar 19, 2024	DEF 14A	DEF 14A
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Mar 15, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Abeona Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Abeona Therapeutics Inc News

Latest updates

Abeona Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4	2020Q3	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2
Revenue	-	-	-	3,500	68.00	-	1,000	346	1,673	3,000	7,000	482	1,709	819	6,275	215	219	217	186	256	184	396
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	18,492	18,625	12,833	11,214	8,965	5,581	8,657	5,470	6,088	5,358	6,929
Operating Expenses	16.5%	13,209	11,334	14,054	13,004	9,380	9,008	20,937	49,652	17,480	13,248	-	18,625	-	-	-	-	-	-	-	-	-
S&GA Expenses	40.3%	5,830	4,156	5,021	5,682	3,890	3,460	4,224	4,375	7,397	4,432	7,631	4,970	4,627	2,878	-	-	-	-	-	-	-
R&D Expenses	3.2%	7,379	7,148	8,523	6,272	5,490	6,658	10,545	12,812	9,243	7,969	9,470	13,150	7,916	8,162	-	-	-	-	-	-	-
Interest Expenses	3.8%	109	105	103	178	157	200	201	53.00	1,388	1,327	2.00	3.00	3.00	3.00	1.00	2.00	-	-	-	-	-
Net Income	-40.2%	-16,591	-11,836	-16,654	-7,121	-6,434	-4,097	-22,044	-46,683	-15,828	-7,237	-17,479	-16,419	-12,243	-10,530	-	-	-	-	-	-	-
Net Income Margin	-21.2%	-15.19*	-12.53*	-8.61*	-28.07*	-43.78*	-36.19*	-34.94*	-28.31*	-6.91*	-8.48*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-59.4%	-9,272	-5,818	-10,360	-14,034	-6,793	-9,013	-13,790	-33,505	-1,643	-10,973	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.2%	64.00	66.00	54.00	53.00	64.00	39.00	45.00	55.00	80.00	119	131	141	151	159	164	175	223	143	159	166	174
Current Assets	-2.7%	56.00	57.00	44.00	43.00	53.00	25.00	30.00	39.00	56.00	68.00	79.00	89.00	98.00	105	109	119	132	50.00	65.00	72.00	89.00
Cash Equivalents	207.2%	14.00	5.00	6.00	5.00	14.00	6.00	6.00	20.00	33.00	44.00	27.00	14.00	13.00	8.00	15.00	40.00	129	48.00	43.00	26.00	19.00
Net PPE	-11.7%	4.00	4.00	4.00	5.00	6.00	7.00	7.00	8.00	12.00	10.00	10.00	11.00	11.00	12.00	13.00	13.00	13.00	14.00	14.00	10.00	9.00
Goodwill	-	-	-	-	-	-	-	-	-	-	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00	32.00
Liabilities	11.6%	49.00	44.00	44.00	35.00	37.00	23.00	25.00	24.00	37.00	39.00	47.00	47.00	49.00	44.00	43.00	43.00	45.00	47.00	52.00	48.00	40.00
Current Liabilities	59.6%	13.00	8.00	9.00	7.00	8.00	13.00	14.00	12.00	17.00	26.00	42.00	41.00	42.00	39.00	38.00	37.00	39.00	20.00	26.00	21.00	20.00
Shareholder's Equity	-32.7%	15.00	22.00	9.00	19.00	27.00	12.00	14.00	21.00	42.00	80.00	84.00	94.00	103	115	121	132	178	96.00	107	118	134
Retained Earnings	-2.3%	-749	-732	-721	-704	-695	688	682	-676	-655	-608	-601	-586	-570	-554	-547	-534	-486	-470	-452	-428	-410
Additional Paid-In Capital	1.2%	764	755	730	723	722	701	694	697	697	688	685	680	672	669	668	666	664	566	559	546	544
Shares Outstanding	7.3%	27.00	25.00	21.00	18.00	18.00	6.00	6.00	6.00	6.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-
Float	-	-	-	78.00	-	-	-	29.00	-	-	-	137	-	-	-	204	-	-	-	131	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-59.9%	-9,235	-5,774	-10,300	-11,700	-13,992	-6,791	-9,013	-13,687	-30,257	-10,334	-11,489	-13,585	-1,610	-10,702	-9,475	-13,232	-14,246	-18,254	-15,242	-15,078	-16,967
Share Based Compensation	-2.8%	1,514	1,557	927	770	833	632	724	862	2,001	2,537	2,428	1,950	3,030	161	147	1,256	2,595	98.00	1,678	2,103	1,106
Cashflow From Investing	161.5%	11,529	-18,743	5,211	2,211	-25,290	1,649	-1,398	1,075	7,999	26,763	21,924	9,376	5,782	4,584	-18,209	-75,871	-946	19,228	18,920	22,774	2,119
Cashflow From Financing	-67.5%	7,467	22,976	6,618	-4.00	42,766	4,189	-	-	16,331	173	2,479	5,878	3.00	-	-	-	96,527	4,340	13,007	28.00	-1.00

ABEO Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
License and other revenues	$ 3,500	$ 1,414
Expenses:
Royalties	1,605	450
Research and development	31,091	28,965
General and administrative	19,004	17,256
Impairment of licensed technology		1,355
Loss/(gain) on operating lease right-of-use assets	(1,065)	2,511
Impairment of construction-in-progress		1,792
Total expenses	50,635	52,329
Loss from operations	(47,135)	(50,915)
Interest income	2,117	431
Interest expense	(418)	(736)
Change in fair value of warrant liabilities	(11,695)	11,383
Other income	2,943	141
Net loss	(54,188)	(39,696)
Deemed dividends related to Series A and Series B Convertible Redeemable Preferred Stock		(3,782)
Net loss attributable to Common Shareholders	$ (54,188)	$ (43,478)
Loss per common share - basic	$ (2.53)	$ (5.53)
Loss per common share - diluted	$ (2.53)	$ (5.53)
Weighted average number of common shares outstanding - basic	21,380,476	7,861,515
Weighted average number of common shares outstanding - diluted	21,380,476	7,861,515
Other comprehensive income (loss):
Change in unrealized gains (losses) related to available-for-sale debt securities	$ 34	$ (99)
Foreign currency translation adjustments	29	(3)
Comprehensive loss	$ (54,125)	$ (43,580)

ABEO Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 14,473	$ 14,217
Short-term investments	37,753	37,932
Restricted cash	338	338
Other receivables	2,444	188
Prepaid expenses and other current assets	729	424
Total current assets	55,737	53,099
Property and equipment, net	3,533	5,741
Operating lease right-of-use assets	4,455	5,331
Other assets	277	43
Total assets	64,002	64,214
Current liabilities:
Accounts payable	1,858	1,811
Accrued expenses	5,985	3,991
Current portion of operating lease liability	998	1,773
Current portion of payable to licensor	4,580
Other current liabilities	1	204
Total current liabilities	13,422	7,779
Long-term operating lease liabilities	4,402	5,854
Warrant liabilities	31,352	19,657
Total liabilities	49,176	37,453
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Common stock - $0.01 par value; authorized 200,000,000 shares; 26,523,878 and 17,719,720 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	265	177
Additional paid-in capital	764,151	722,049
Accumulated deficit	(749,524)	(695,336)
Accumulated other comprehensive loss	(66)	(129)
Total stockholders’ equity	14,826	26,761
Total liabilities and stockholders’ equity	64,002	64,214
Related Party [Member]
Current liabilities:
Payable to licensor		$ 4,163

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

CEO	Dr. Vishwas Seshadri M.B.A., Ph.D.
WEBSITE	abeonatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	57

Abeona Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Abeona Therapeutics Inc? What does ABEO stand for in stocks?

ABEO is the stock ticker symbol of Abeona Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abeona Therapeutics Inc (ABEO)?

As of Fri Apr 26 2024, market cap of Abeona Therapeutics Inc is 89.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers. The fair value of Abeona Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abeona Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABEO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abeona Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ABEO is over valued or under valued. Whether Abeona Therapeutics Inc is cheap or expensive depends on the assumptions which impact Abeona Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABEO.

What is Abeona Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ABEO's PE ratio (Price to Earnings) is -1.66 and Price to Sales (PS) ratio is 25.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abeona Therapeutics Inc's stock?

In the past 10 years, Abeona Therapeutics Inc has provided -0.182 (multiply by 100 for percentage) rate of return.